John A. Barranger
Affiliations: | 1990-2005 | University of Pittsburgh, Pittsburgh, PA, United States |
Area:
Molecular Biology, GeneticsWebsite:
https://www.utimes.pitt.edu/archives/?p=30977Google:
"John Barranger"Bio:
(1945 - 2014)
Parents
Sign in to add mentor| Samuel P. Bessman | grad student | 1974 | USC | |
| (The implications of multiple forms of phenylalanine hydroxylase in phenylketonuria and related diseases on phenylalanine metabolism) | ||||
Children
Sign in to add trainee| Johannes Maria Franciscus Gerardus (Hans) Aerts | grad student | 1988 | Amsterdam (Chemistry Tree) |
| Michael J. Vallor | grad student | 2001 | University of Pittsburgh |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Barranger JA, Brady RO, Grabowski GA, et al. (2014) Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014. American Journal of Hematology. 89: 457-8 |
| Barranger JA, Gambello MJ, Goker-Alpan O, et al. (2014) Evaluation of glycosphingolipid clearance in patients with Fabry disease treated with agalsidase alfa who switched to agalsidase beta (the INFORM study) Molecular Genetics and Metabolism. 111 |
| Weinreb NJ, Barranger JA, Charrow J, et al. (2005) Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. American Journal of Hematology. 80: 223-9 |
| Cabrera-Salazar MA, O'Rourke E, Charria-Ortiz G, et al. (2005) Radiological evidence of early cerebral microvascular disease in young children with Fabry disease. The Journal of Pediatrics. 147: 102-5 |
| Cabrera-Salazar MA, O'Rourke E, Henderson N, et al. (2004) Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy. Clinica Chimica Acta; International Journal of Clinical Chemistry. 344: 101-7 |
| Cabrera-Salazar MA, Barranger JA. (2004) Surrogate markers for lysosomal storage Blood. 103: 2-3 |
| Desnick RJ, Brady R, Barranger J, et al. (2003) Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy Annals of Internal Medicine. 138: 338-346 |
| Marshall J, McEachern KA, Kyros JA, et al. (2002) Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model. Molecular Therapy : the Journal of the American Society of Gene Therapy. 6: 179-89 |
| Barranger JA, O'Rourke E. (2001) Lessons learned from the development of enzyme therapy for Gaucher disease. Journal of Inherited Metabolic Disease. 24: 89-96; discussion 87 |
| Matzner U, Harzer K, Learish R, et al. (2000) Long-term expression and transfer of arylsulfatase A into brain of arylsulfatase A-deficient mice transplanted with bone marrow expressing the arylsulfatase A cDNA from a retroviral vector. Gene Therapy. 7: 1250-1257 |